Aptinyx Suffers Defeat in Diabetic Peripheral Neuropathy as Drug Fails Endpoint

Aptinyx reported Thursday that its therapeutic NYX-2925, intended to treat painful diabetic peripheral neuropathy (DPN), failed to produce significant results in Phase IIb clinical trials.